stockportfolio.pro
ARWR vs KRYS: Which Stock Is the Better Buy?
Arrowhead Pharmaceuticals, Inc. and Krystal Biotech, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ARWR vs KRYS, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Arrowhead Pharmaceuticals, Inc. (ARWR) | Krystal Biotech, Inc. (KRYS) | |
|---|---|---|
| Market cap | $10.0B | $9.2B |
| Revenue (latest FY) | $829.45M | $389.13M |
| Net income (latest FY) | $-1.63M | $204.83M |
| Revenue growth (5y CAGR) | 56.6% | — |
| Net margin | -0.2% | 52.6% |
| Return on equity | -0.3% | 16.8% |
| P/E ratio | — | 42.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 3 |
| Positive free cash flow | Yes | Yes |
See the full ARWR vs KRYS breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ARWR's full financials → Open KRYS's full financials →More comparisons
Frequently asked questions
Which is bigger, ARWR or KRYS?
Arrowhead Pharmaceuticals, Inc. is larger by market capitalization — $10.0B versus $9.2B.
Which grows faster, ARWR or KRYS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.